Updated:
3SBio Inc.
Founded by Jing Lou in 1993, 3SBio Inc. is a Chinese biopharma listed in Hong Kong, with marketed therapies in nephrology, oncology, and immunology.
3SBio Inc.
3SBio Inc., established in 1993 by Chairman and CEO Jing Lou, is a Chinese biotechnology company focused on the research, development, manufacture, and commercialization of recombinant protein drugs and biosimilars. The firm began as a small R&D venture in Shenyang and listed on the Hong Kong Stock Exchange in 2015, raising roughly $700 million in its IPO (per Reuters, 2015). 3SBio's strategy centers on in-house development of complex biologics and strategic licensing from Western partners. Its marketed portfolio includes EPO products (epoetin alfa), thrombopoietin agonists (rhTPO), and biosimilars for autoimmune diseases. The company has a pipeline across oncology, nephrology, and ophthalmology, with a strong focus on the Chinese market. Over the years it has in-licensed assets from companies like Takeda, Swedish Orphan Biovitrum, and Bellicum Pharmaceuticals. The firm operates manufacturing facilities in Shenyang and Shanghai, and maintains commercial and regulatory offices in Beijing and Menlo Park, California. It employs a sales force of roughly 2,000 covering hospitals across China. In 2023 the firm began commercializing a biosimilar of aflibercept for ophthalmology, licensed from a European biotech (per 3SBio press release, March 2023). 3SBio's structural differentiator is its dual identity: it is both a fully integrated Chinese biopharma with a revenue-generating product portfolio and a public company governed by Hong Kong listing rules, giving it transparency and corporate governance standards atypical for Chinese biotechs. This hybrid — public, profitable, and still founder-controlled — makes it a unique entity in Chinese biotech.
General information
Firm type
other
Year founded
1993
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Shenyang
Corporate office
Shenyang, Liaoning, China
Additional offices
Menlo Park, CA, United States · Shanghai, China · Beijing, China
Principals
Jing Lou
Chairman of the Board & Chief Executive Officer
David Pinchot
Chief Financial Officer
Hui Chen
Senior Vice President, R&D
Sector focus
Frequently asked questions
Who founded 3SBio Inc. and when was the firm established?
Jing Lou founded 3SBio in 1993. He remains Chairman and CEO. The company listed on the Hong Kong Stock Exchange in 2015.
Is 3SBio a family office or a biopharmaceutical company?
3SBio is a publicly traded biopharmaceutical company engaged in developing, manufacturing, and commercializing recombinant protein drugs and biosimilars, primarily in China.
What therapeutic areas does 3SBio focus on?
Its marketed products and pipeline concentrate on nephrology (e.g., EPO), oncology (e.g., rhTPO), immunology (biosimilars), and ophthalmology (aflibercept biosimilar).
How does 3SBio source its drug pipeline?
The firm combines internal R&D with in-licensing of late-stage biologics from Western biotechs. It has partnered with Takeda, Swedish Orphan Biovitrum, and Bellicum Pharmaceuticals to bring assets into China.
Where are 3SBio's facilities located?
The firm's headquarters and principal manufacturing are in Shenyang, with additional manufacturing and R&D in Shanghai, and commercial/regulatory offices in Beijing and Menlo Park, California.
Has 3SBio raised public capital, and is it profitable?
3SBio raised approximately $700 million in its 2015 Hong Kong IPO. The firm has been operationally profitable in most recent fiscal years, with its marketed product portfolio generating recurring revenue.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: